Denali Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:DNLI) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Cash from operating activities 59.14 M83.72 M131.47 M75.3 M107.3 M98.54 M 412.6 M Cash from investing activities -93.66 M-172.21 M18.75 M157.94 M57.83 M20.77 M 255.28 M Cash from financing activities -18.56 M-4.17 M3.76 M-1.62 M778 K186.3 M 189.22 M Free cash flow 55.26 M78.62 M126.39 M71.02 M108.67 M97.01 M 403.1 M

뉴스

DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus

울프 리서치, 데날리 테라퓨틱스에 ’피어퍼폼’ 투자의견 제시

Wolfe Research initiates Denali Therapeutics stock with Peerperform

Denali Therapeutics Inc. (DNLI) Presents at 22nd Annual WORLDSymposium - Slideshow (NASDAQ:DNLI) 2026-02-06

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call - Slideshow (NASDAQ:DNLI) 2026-02-05

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Denali to present clinical data on rare disease therapies at WORLDSymposium

데날리 테라퓨틱스, 파이프라인 진전으로 골드만삭스 ’매수’ 등급 유지

Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up